Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Desnica B et al. Myalgia and swelling of interphalangeal joints as side-effect of prolonged azithromycin therapy in patient with pelvic actinomycosis: case report. 2007 Scand. J. Infect. Dis. pmid:17366044
Dakdouki GK et al. Azithromycin-induced rash in infectious mononucleosis. 2002 Scand. J. Infect. Dis. pmid:12587634
Brihmer C et al. Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women. 1996 Scand. J. Infect. Dis. pmid:8953672
Kuzman I et al. Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. 1995 Scand. J. Infect. Dis. pmid:8588143
Schönwald S et al. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. 1994 Scand. J. Infect. Dis. pmid:7747094
Brandén E et al. Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection. 2004 Scand. J. Infect. Dis. pmid:15764166
Nyström-Rosander C et al. Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations. 1997 Scand. J. Infect. Dis. pmid:9435043
Colakoglu S et al. Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Ankara, Turkey. 2006 Scand. J. Infect. Dis. pmid:16798693
Müller S et al. Resistance to ampicillin, third-generation cephalosporins, ciprofloxacin, co-trimoxazole and azithromycin in clinical isolates of Salmonella enterica subsp. enterica from Germany: real problem or sporadic circumstance? 2011 Scand. J. Infect. Dis. pmid:21265586
Chini P et al. Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. 2012 Scand. J. Gastroenterol. pmid:22364597
Tabbara KF et al. Azithromycin prophylaxis and treatment of murine toxoplasmosis. 2005 Saudi Med J pmid:15806206
Vafaeimanesh J et al. Expression comparison of azithromycin and clarithromycin in triple-therapy regimens for eradication of Helicobacter pylori in hemodialysis patients. 2014 Saudi J Kidney Dis Transpl pmid:24434382
Agah S et al. Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for Helicobacter pylori eradication in dyspepsia. 2009 Oct-Dec Saudi J Gastroenterol pmid:19794266
Drake WP et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. 2013 Sarcoidosis Vasc Diffuse Lung Dis pmid:24284293
Elias AF et al. Typhoid fever in a young immigrant child: a case report and review of the literature. 2008 S D Med pmid:18717293
Gologan R et al. Multiple myeloma in remission complicated by bone marrow granulomas. 2003 Rom J Intern Med pmid:15526516
Toledo Junior A et al. Poor response to azithromycin in cutaneous leishmaniasis leading to a premature interruption of a multicentric phase III clinical trial in Brazil. 2014 Nov-Dec Rev. Soc. Bras. Med. Trop. pmid:25626655
Gakiya E et al. [Experimental infection in mice by Plasmodium berghei: an evidence of antiparasitic action of azithromycin]. 2001 Mar-Apr Rev. Soc. Bras. Med. Trop. pmid:11391444
Braz LM et al. [The evaluation of the efficacy of azithromycin and pyrimethamine used alone or in combination in the treatment of an experimental infection in mice by Toxoplasma gondii]. 1999 Jul-Aug Rev. Soc. Bras. Med. Trop. pmid:10495670
Sinagra A et al. The activity of azithromycin against Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis in the golden hamster model. 2007 Nov-Dec Rev. Soc. Bras. Med. Trop. pmid:18200413
Lescano SA et al. [Evaluation of the efficacy of azithromycin and pyrimethamine, for treatment of experimental infection of mice with Toxoplasma gondii cystogenic strain]. 2004 Nov-Dec Rev. Soc. Bras. Med. Trop. pmid:15765594
Prata A et al. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. 2003 Jan-Feb Rev. Soc. Bras. Med. Trop. pmid:12715065
Silva-Vergara ML et al. Azithromycin in the treatment of mucosal leishmaniasis. 2004 May-Jun Rev. Inst. Med. Trop. Sao Paulo pmid:15286825
Teixeira AC et al. Low efficacy of azithromycin to treat cutaneous leishmaniasis in Manaus, AM, Brazil. 2007 Jul-Aug Rev. Inst. Med. Trop. Sao Paulo pmid:17823753
Teixeira AC et al. Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil. 2008 May-Jun Rev. Inst. Med. Trop. Sao Paulo pmid:18604416
Faucher P and Madelenat P [Induced abortion]. 2006 Rev Prat pmid:17139871
Vaz AP et al. [Azithromycin as an adjuvant therapy in cryptogenic organizing pneumonia]. 2011 Jul-Aug Rev Port Pneumol pmid:21652172
Santos N et al. QT interval prolongation and extreme bradycardia after a single dose of azithromycin. 2010 Rev Port Cardiol pmid:20391905
Bedos JP and Veber B [Lower respiratory infections: predictive factors of therapeutic response]. 1996 Rev Pneumol Clin pmid:9033917
Zuck P [Efficacy of a 5-day treatment with an azalide (azithromycin) in superinfections of chronic bronchitis]. 1996 Rev Pneumol Clin pmid:9033919
Díaz Sánchez M et al. [New medications: azithromycin]. 1993 Jul-Sep Rev Med Univ Navarra pmid:8134755
Baumgartner JD and Christin L [2011 news in infections diseases: selected readings]. 2012 Rev Med Suisse pmid:22303737
Diezi L et al. [Pharmacovigilance update]. 2014 Rev Med Suisse pmid:24558915
Widikker I and Rochat T [Pulmonary medicine. Four major papers in 2010-2011]. 2012 Rev Med Suisse pmid:23185822
Scheen AJ [Pharma-clinics. Drug of the month. Azithromycin (Zitromax)]. 1995 Rev Med Liege pmid:7481274
Sasseigne G et al. [Fever and abdominal pain in a 56-year-old woman]. 2009 Rev Med Interne pmid:19815317
Diculencu D et al. [The postantibiotic effect of azithromycin on respiratory pathogens]. 1998 Jul-Dec Rev Med Chir Soc Med Nat Iasi pmid:10756861
Diculencu D et al. [The postantibiotic effect of azithromycin on respiratory pathogens]. 1996 Jul-Dec Rev Med Chir Soc Med Nat Iasi pmid:9455450
Eymin G et al. [Cat-scratch disease. Review of eight adult patients hospitalized for fever or adenopathy]. 2006 Rev Med Chil pmid:17186093
Flores S et al. [Triple therapy of short-term with azithromycin, amoxycillin and omeprazole for the eradication of Helicobacter pylori]. 2000 Rev Med Chil pmid:11008354
Uribe P et al. [Bacillary angiomatosis]. 2012 Rev Med Chil pmid:23282705
Abely M et al. [National consensus regarding azithromycin use in cystic fibrosis]. 2015 Rev Mal Respir pmid:26003196
Silva FM et al. Low efficacy of an ultra-short term, once-daily dose triple therapy with omeprazole, azithromycin, and secnidazole for Helicobacter pylori eradication in peptic ulcer. 2002 Jan-Feb Rev Hosp Clin Fac Med Sao Paulo pmid:12170343
López-Fabal F et al. [In vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit]. 2008 Rev Esp Quimioter pmid:18792821
Alvarez MP et al. [Pharmacovigilance study of azithromycin tablets (500 mg) in the treatment of adult patients with respiratory tract infections]. 2000 Rev Esp Quimioter pmid:11086281
Toro C et al. [Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid]. 2001 Rev Esp Quimioter pmid:11704771
Gómez J et al. [Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD]. 2000 Rev Esp Quimioter pmid:11498704
Fernández Cuenca F et al. [In vitro activity of azithromycin against clinical isolates of Acinetobacter baumannii]. 2003 Rev Esp Quimioter pmid:12973458
Calvo A et al. [Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae]. 2001 Rev Esp Quimioter pmid:11856980
Sánchez F et al. [Treatment of pneumonia caused by Legionella with azithromycin]. 1998 Rev Esp Quimioter pmid:9795300
Rivero-Sánchez L et al. Fitz-Hugh-Curtis syndrome: abdominal pain in women of 26 years old. 2011 Rev Esp Enferm Dig pmid:22054272
de Górgolas Hernández-Mora M et al. [Therapeutic approaches to cryptosporidiosis. A review of the literature]. 1993 Rev Clin Esp pmid:8259458
Cofré Guerra J [Pertussis chemoprophylaxis: a sterile effort?]. 2006 Rev Chilena Infectol pmid:16462967
Ruíz del Olmo I et al. [Severe neutropenia as side effect of medical treatment in nontuberculous mycobacterial adenitis]. 2015 Rev Chilena Infectol pmid:26633119
Aires FT et al. Efficacy of azithromycin on the treatment of syphilis. 2010 Sep-Oct Rev Assoc Med Bras (1992) pmid:21152813
Bowen BE et al. Diagnostic and therapeutic challenges. 2011 Retina (Philadelphia, Pa.) pmid:21866076
Khairallah M et al. Acute choroidal ischemia associated with toxoplasmic retinochoroiditis. 2007 Retina (Philadelphia, Pa.) pmid:17891022
Soepandi P et al. The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. 1998 Respirology pmid:9692520
Diego AD et al. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. 2013 Respirology pmid:23714268
Karabay O Is azithromycin prophylaxis a rational approach for bronchoscopic biopsy? 2007 Respirology pmid:17587436
Singh N All generalizations are false including this one. 2007 Respirology pmid:17587437
Hodge S et al. Increased CD8 T-cell granzyme B in COPD is suppressed by treatment with low-dose azithromycin. 2015 Respirology pmid:25308201
Lourdesamy Anthony AI and Muthukumaru U Efficacy of azithromycin in the treatment of bronchiectasis. 2014 Respirology pmid:25183304
Kanazawa H Efficacy of azithromycin administration in prevention of respiratory tract infection after bronchoscopic biopsy: a randomized, controlled trial. 2007 Respirology pmid:17207028
Smith DJ et al. Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres. 2016 Respirology pmid:26711802
Wong C and Jones S Oxidative stress and macrolides in bronchiectasis--exhaling few clues. 2013 Respirology pmid:23890203
Hansbro PM and Jarnicki AG Macrolides for macrophages in chronic obstructive pulmonary disease. 2012 Respirology pmid:22563902
Hodge S and Reynolds PN Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. 2012 Respirology pmid:22288725
Hanon S et al. Evidence of improved small airways function after azithromycin treatment in diffuse panbronchiolitis. 2012 Respiration pmid:22759949
Kawamura K et al. Efficacy of azithromycin for treatment of acute exacerbation of chronic fibrosing interstitial pneumonia: a prospective, open-label study with historical controls. 2014 Respiration pmid:24802885
Ballard HO et al. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. 2007 Respir. Res. pmid:17550598
Persson HL et al. Leaky lysosomes in lung transplant macrophages: azithromycin prevents oxidative damage. 2012 Respir. Res. pmid:23006592
Ra SW et al. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. 2017 Respir. Res. pmid:28558695
Beigelman A et al. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. 2010 Respir. Res. pmid:20591166
Berkhof FF et al. Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. 2013 Respir. Res. pmid:24229360
Lendermon EA et al. Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation. 2017 Respir. Res. pmid:28659178
Legssyer R et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. 2006 Respir. Res. pmid:17064416
Niederman MS et al. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. 2006 Respir Med pmid:16531032
Haworth CS et al. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. 2014 Respir Med pmid:25301290
Samson C et al. Long-term effects of azithromycin in patients with cystic fibrosis. 2016 Respir Med pmid:27492507
Equi AC et al. Exploring the mechanisms of macrolides in cystic fibrosis. 2006 Respir Med pmid:16185859
DeAbate CA et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. 2000 Respir Med pmid:11127487
Cazzola M et al. Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae. 2005 Respir Med pmid:15878482
Anwar GA et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. 2008 Respir Med pmid:18653323
Steinkamp G et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. 2008 Respir Med pmid:18701270
Simoens S et al. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. 2013 Respir Med pmid:23352223
de Wall C et al. Home spirometry as early detector of azithromycin refractory bronchiolitis obliterans syndrome in lung transplant recipients. 2014 Respir Med pmid:24445061
Naderi N et al. Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease. 2018 Respir Med pmid:29724384
Kamio K and Azuma A Diffuse panbronchiolitis: A fine road from the discovery of a disease to the establishment of treatment. 2018 Respir Investig pmid:30049592
Wan YF et al. Azithromycin attenuates pulmonary inflammation and emphysema in smoking-induced COPD model in rats. 2015 Respir Care pmid:25249648
Escudero E et al. Pharmacokinetics and tissue tolerance of azithromycin after intramuscular administration to rabbits. 2006 Res. Vet. Sci. pmid:16530237
Ramalho VL et al. Comparison of azithromycin and oral hygiene program in the treatment of cyclosporine-induced gingival hyperplasia. 2007 Ren Fail pmid:17497438
Krásny J et al. The role of Chlamydia pneumoniae in the etiology of keratoconjunctivitis sicca (KCS). 2014 Recent Pat Inflamm Allergy Drug Discov pmid:25395268
Debremaeker D et al. Analysis of unknown compounds in azithromycin bulk samples with liquid chromatography coupled to ion trap mass spectrometry. 2003 Rapid Commun. Mass Spectrom. pmid:12569445
Zhou F et al. High accuracy mass measurement of peptides with internal calibration using a dual electrospray ionization sprayer system for protein identification. 2002 Rapid Commun. Mass Spectrom. pmid:11870887
Bascones-Martinez A et al. Prevention of alveolar osteitis with azithromycin in women according to use of tobacco and oral contraceptives. 2007 Quintessence Int pmid:17432784
Kikuchi Y et al. Hyperoxia exaggerates bacterial dissemination and lethality in Pseudomonas aeruginosa pneumonia. 2009 Pulm Pharmacol Ther pmid:19162211
Mertens TC et al. Azithromycin differentially affects the IL-13-induced expression profile in human bronchial epithelial cells. 2016 Pulm Pharmacol Ther pmid:27246785
Blasi F et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. 2010 Pulm Pharmacol Ther pmid:20025989
Kai T et al. A low concentration of azithromycin inhibits the mRNA expression of N-acyl homoserine lactone synthesis enzymes, upstream of lasI or rhlI, in Pseudomonas aeruginosa. 2009 Pulm Pharmacol Ther pmid:19393329